Intensity Therapeutics Inc. (NASDAQ:INTS) Sees Large Growth in Short Interest

Intensity Therapeutics Inc. (NASDAQ:INTS) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 126,421 shares, an increase of 117.2% from the June 15th total of 58,214 shares. Based on an average daily volume of 76,377 shares, the short-interest ratio is currently 1.7 days. Currently, 5.1% of the company’s stock are short sold.

Analyst Ratings Changes

INTS has been the topic of several research reports. Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. Weiss Ratings downgraded Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Finally, Freedom Capital upgraded Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.50.

Institutional Trading of Intensity Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of INTS. Jane Street Group LLC acquired a new position in shares of Intensity Therapeutics in the fourth quarter worth about $26,000. Corient Private Wealth LLC purchased a new stake in Intensity Therapeutics during the 4th quarter worth approximately $41,000. State Street Corp increased its holdings in Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the last quarter. Legacy Advisors LLC purchased a new stake in Intensity Therapeutics during the 4th quarter worth approximately $63,000. Finally, Mesirow Financial Investment Management Inc. raised its position in shares of Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares in the last quarter. 3.74% of the stock is owned by hedge funds and other institutional investors.

Intensity Therapeutics Trading Up 1.2%

NASDAQ INTS opened at $4.90 on Friday. The stock has a market cap of $13.23 million, a P/E ratio of -0.86 and a beta of 2.78. The company’s fifty day simple moving average is $4.35 and its 200-day simple moving average is $6.37. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a 52 week low of $3.51 and a 52 week high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.12. Equities research analysts predict that Intensity Therapeutics will post -2.7 EPS for the current fiscal year.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.